ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
03 October 2023 - 7:05AM
ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”)
(Nasdaq: ALXO), an immuno-oncology company developing therapies
that block the CD47 immune checkpoint pathway, today announced the
hosting of an investor call and webcast on Tuesday, October 3rd at
8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial
results of evorpacept for the treatment of advanced HER2-positive
gastric cancer.
To access the live conference call, please dial (800) 715-9871
(U.S./Canada) or +44.800.260.6466 (internationally), Conference ID
7797378. To access the live and archived webcast of the conference
call, please visit the News & Events section (see
“Events") of the Company’s website at www.alxoncology.com
where a slide presentation will be referenced during the event.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 immune checkpoint
inhibitor and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain.
Evorpacept has demonstrated promising clinical responses across a
range of hematologic and solid malignancies in combination with a
number of leading anti-cancer antibodies. ALX Oncology is currently
focusing on combining evorpacept with anti-cancer antibodies, ADCs,
and PD-1/PD-L1 immune checkpoint inhibitors.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
mchatterjee@bplifescience.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Apr 2024 to May 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From May 2023 to May 2024